Computational Breakthrough Identifies Potent Stigmasterol Analogs as Promising Alzheimer’s Therapeutics
Virtual screening of 972 stigmasterol analogs has revealed three lead candidates with enhanced binding affinity and drug-like properties compared to current Alzheimer’s treatments. The compounds demonstrate improved blood-brain barrier penetration potential and favorable toxicity profiles, positioning them as promising therapeutic candidates.
Computational Discovery of Enhanced Alzheimer’s Inhibitors
Researchers have identified three stigmasterol-derived compounds with superior acetylcholinesterase (AChE) inhibition potential through advanced computational screening methods, according to recent scientific reports. The study, which employed high-throughput virtual screening of 972 stigmasterol analogs, reportedly uncovered candidates that outperform both the natural compound stigmasterol and the commonly prescribed Alzheimer’s drug donepezil in binding affinity and drug-like properties.